Open AccessEVALUATION OF UVEITIS ACTIVITY USING BOS24 IN PATIENTS WITH BEHСET'S DISEASE
Author(s) -
Т. А. Лисицына,
Г. А. Давыдова,
З. Р. Хатагова,
Л. А. Катаргина,
Z S Alekberova
Publication year - 2017
Publication title -
naučno-praktičeskaâ revmatologiâ
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.137
H-Index - 9
eISSN - 1995-4492
pISSN - 1995-4484
DOI - 10.14412/1995-4484-2016-681-686
Subject(s) - medicine , uveitis , exacerbation , behcet's disease , azathioprine , anterior uveitis , eye disease , ophthalmology , gastroenterology , disease
Objective: to estimate changes of uveitis activity using BOS24 (Behсet's disease Ocular attack Score 24) during antiinflammatory and immunosuppressive therapy in patients with Behcet's disease (BD). Subjects and methods. 103 (75.6%) of the 138 patients with BD fulfilled the 1990 International Study Group for Behсet's Disease (ISGBD) criteria had eye lesions; 55 (53.4%) of the 103 patients had an exacerbation of uveitis. 55 patients with an exacerbation of uveitis were found to have active inflammation in 94 eyes. The activity of uveitis was monitored during anti-inflammatory and immunosuppressive therapy, by using BOS24 that consists of 6 parameters with maximal possible value 24. Results and discussion. The mean BOS24 for 94 eyes with active uveitis at baseline was 9.33±0.91. The most pronounced inflammatory changes were found in the posterior chamber of the eye, mainly in the area of the peripheral retina, rarely in the area of the fovea and in the optic disc. All the patients with an exacerbation of uveitis received systemic therapy with glucocorticoids, cyclosporine and/or azathioprine. After 8.92±3.47 months of treatment, the mean BOS2 decreased significantly (p < 0.001) to 2.20±1.02. The most substantial positive changes were noted in the anterior chamber of the eye (p = 0.03), vitreous humor (p < 0.01), and peripheral retina (p < 0.001). Conclusion . BOS24 is a reliable tool to quantify uveitis activity in patients with BD and its dynamics during antiinflammatory and immunosuppressive therapy.